Drs. Susruta Majumdar and Abdelfattah Faouzi recently co-published a paper in the Journal of Medicinal Chemistry highlighting their work to uncover a compound that could play a key role in the future development of alternative therapeutics for pain management.
They served as the lead authors on the paper, which represented a collaboration of more than 15 researchers from a variety of prestigious institutions including the Icahn School of Medicine at Mount Sinai, Memorial Sloan Kettering Cancer Center, Rutgers Robert Wood Johnson Medical School, University of Arizona Health Sciences College of Medicine Tucson and Washington University School of Medicine in St. Louis.
Over the past three years, the researchers have studied a series of carfentanyl amide-based opioid derivatives targeting the mu and delta opioid receptor complexes with the overall goal of identifying a safe, pharmacological agent with the ability to provide pain relief without the usual adverse side effects associated with conventional, clinical opioids, such as addiction and respiratory depression.
Read the full manuscript here: https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c00901